Introduction to Pemazyre (Pemigatinib) 13.5mg 

Pemazyre (Pemigatinib) 13.5mg is a prescription medicine used for the treatment of certain types of cancers, particularly cholangiocarcinoma (bile duct cancer) with FGFR2 gene alterations. It is a targeted therapy that helps slow or stop cancer growth.

PEMINIB 13.5mg is classified under Prescription Medicines, Oncology Medicines, Targeted Cancer Therapies, and Fibroblast Growth Factor Receptor (FGFR) Inhibitors. It contains Pemigatinib, which works by blocking abnormal signals that promote cancer cell growth.

In many countries, Pemazyre is the original brand containing the same active ingredient Pemigatinib, offering similar therapeutic benefits when prescribed by a qualified healthcare professional.

What Is Pemazyre (Pemigatinib) 13.5mg? 

Pemazyre is the brand name for Pemigatinib, an oral targeted anticancer medication.

Pemigatinib belongs to a class of medicines known as FGFR Inhibitors. These medicines specifically target fibroblast growth factor receptors involved in tumor growth.

Generic versions such as PEMINIB 13.5mg contain the same active compound and may be used depending on physician recommendation and availability.

Drug Class and Mechanism of Action 

Pemigatinib is classified as a targeted anticancer agent with kinase inhibition properties.

How Pemigatinib Works 

It works in several ways:

• Inhibits FGFR1, FGFR2, and FGFR3 receptors
• Blocks cancer cell signaling pathways
• Slows tumor growth and progression

Through these mechanisms, Pemigatinib helps control cancer development.

How Pemazyre Works in the Body 

Certain cancers are driven by FGFR gene alterations that lead to uncontrolled cell growth.

Key Actions of Pemigatinib 

• Targets FGFR gene abnormalities
• Inhibits tumor cell proliferation
• Helps reduce tumor size

PEMINIB 13.5mg provides precision oncology treatment for FGFR-driven cancers.

Medical Uses of Pemazyre (Pemigatinib) 13.5mg 

PEMINIB 13.5mg is used in specific cancer treatments.

Cholangiocarcinoma (Bile Duct Cancer) 

Used in patients with FGFR2 fusion or rearrangement.

Potential Benefits 

• Targeted tumor control
• Improved progression-free survival
• Personalized cancer therapy

Who Can Take PEMINIB 13.5mg? 

This medicine should be used under specialist oncology supervision.

Eligibility Criteria 

Patients may be prescribed PEMINIB if they:

• Have FGFR2-positive cholangiocarcinoma
• Have undergone genetic testing
• Require targeted therapy

Who Should Avoid Pemazyre (Pemigatinib) 13.5mg 

This medicine should NOT be used by:

• Patients with hypersensitivity to Pemigatinib
• Pregnant or breastfeeding women (unless advised)
• Individuals with severe uncontrolled medical conditions

Pemazyre (Pemigatinib) 13.5mg Dosage and Administration 

Standard Dosage Guidelines 

Typical dosage includes:

• PEMINIB 13.5mg taken once daily
• Usually in cycles (e.g., 14 days on, 7 days off)
• Taken with or without food

Dosage Adjustments 

Doctors may adjust dosage depending on:

• Side effects
• Liver and kidney function
• Treatment response

Side Effects of Pemazyre (Pemigatinib) 13.5mg

Like all cancer medicines, Pemigatinib may cause side effects.

Common Side Effects 

• Fatigue
• Diarrhea
• Dry mouth
• Nail changes

Serious Side Effects 

• Eye problems (retinal disorders)
• High phosphate levels (hyperphosphatemia)
• Liver toxicity

Patients should report vision changes or unusual symptoms immediately.

Storage:
Store below 25°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.

Frequently Asked Questions (FAQs) 

1. Is Pemazyre safe for long-term use? 

Yes, under oncologist supervision.

2. Is PEMINIB 13.5mg chemotherapy? 

No. It is a targeted therapy.

3. Do I need genetic testing before use? 

Yes, FGFR mutation testing is required.

4. How does PEMINIB work? 

It blocks FGFR pathways involved in cancer growth.

5. Can it cure cancer? 

It helps control cancer but may not cure it.

6. Is PEMINIB the same as Pemazyre? 

Yes. Both contain Pemigatinib.

7. Do I need a prescription for PEMINIB 13.5mg? 

Yes. It is a prescription-only oncology medicine.

Medical Disclaimer 

Disclaimer:
This content is for educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional before using this medication.